Connect Biopharma Holdings Ltd
NASDAQ: CNTB · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Connect Biopharma Holdings Ltd (CNTB) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-69.03M | $-13.09M | $-25.61M | $-544.93M | $-99.27M | $-47.93M | $-23.61M | $-51.21M |
| Capital expenditures | $1.19M | $155522.00 | $2.34M | $47.53M | $4.28M | $294000.00 | $750000.00 | $434000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $562173.00 | $590644.00 | $57.86M | $1.01M | $3.26M | $6.73M | $3.73M |
| Free cash flow | $-70.22M | $-13.25M | $-27.95M | $-592.46M | $-103.55M | $-48.22M | $-24.36M | $-51.64M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $243000.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Connect Biopharma Holdings Ltd's revenue?
Connect Biopharma Holdings Ltd's trailing twelve-month revenue is $233000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is CNTB?
In its most recent fiscal year, CNTB ran a gross margin of 100.00%, an operating margin of -90,740.63%, and a net margin of -86,687.50%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CNTB generate?
CNTB produced $-51.64M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CNTB's balance sheet healthy?
CNTB holds $38.34M in cash and equivalents against — in long-term debt, on $41.98M of shareholder equity. That debt is best read against the cash flow the business throws off each year.